NodThera Limited
https://nodthera.com/home
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NodThera Limited
Finance Watch: Mega-Rounds Balance Out Influx Of Smaller VC Deals
Private Company Edition: The amount of venture capital investment in biopharma companies has shrunk from quarter to quarter, but the average deal size remained high until the third quarter. Larger rounds from Treeline, Odyssey and Neumora offset a plethora of smaller VC financings early in Q4.
Novo Ventures Remains Bullish After ‘Very Active’ Year
In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.
Roche Bulks Up In NLRP3 With €380m Inflazome Buy
Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.
Novo Holdings Going Big In Asia, CEO Talks Investment Plans
Innovation has come of age in Asia, throwing up investment opportunities in China, Singapore and other Southeast Asian countries that Novo Holdings plans to tap into, says CEO Kasim Kutay. The firm's Asia head, Amit Kakar, also outlines therapeutic areas of interest for the company, which is managing $65bn worth of assets.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice